#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Still's disease Fontan procedure Heart disease congenital Mitochondrial encephalomyopathy Fibrosarcoma Hepatocellular carcinoma Immune-mediated myositis Congenital aplastic anaemia Infection in an immunocompromised host Non-Hodgkin's lymphoma Extranodal marginal zone B-cell lymphoma (MALT type) Epilepsy with myoclonic-atonic seizures Mucopolysaccharidosis II Acquired C1 inhibitor deficiency Huntington's disease More trials…

    Learn about Rare Diseases

    Cholangitis sclerosing – Life with Disease Chronic granulomatous disease – Trials in Disease Rett syndrome – Basic Information Nephroblastoma – Treatment Waldenstrom’s macroglobulinaemia – Basic Information Splenic marginal zone lymphoma – Life with Disease Atypical teratoid/rhabdoid tumour of CNS – Trials in Disease Alagille syndrome – Life with Disease Rhabdoid tumour Breast angiosarcoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Olopatadine Hydrochloride At-1501 Fluticasone Av-Ec2023 L-PHENYLALANINE Apalutamide Diroximel Fumarate Sparsentan Eo2317 Setrusumab Perindopril Arginine Florquinitau (18F) HYDROMORPHONE HYDROCHLORIDE Mycophenolate Mofetil Fedratinib Brentuximab Vedotin Other Blood Products VORMATRIGINE Mosaic Hbcoreag Ammonium Chloride Bp More therapies…

    Learn about Your Condition

    Inclusion body myositis Lymphocytic lymphoma Multiple sclerosis Schizophreniform disorder Hyperthyroidism Usher's syndrome Schizoaffective disorder Neoplasm Hereditary ataxia Supranuclear palsy Lung disorder Neonatal hyperglycaemia Myocarditis High-grade B-cell lymphoma Basal cell carcinoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer male

  • Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Pembrolizumab
    Germany

  • Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    Investigated Diseases:
    • Biliary cancer metastatic
    • Breast cancer recurrent
    • Breast cancer stage IV
    Investigated Drugs:
    • Ds-3939A
    Belgium France Spain

  • Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer male
    • Human epidermal growth factor receptor negative
    • Breast cancer
    Investigated Drugs:
    • Elacestrant
    • Ribociclib
    Austria Germany Spain

  • Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer male
    • Breast cancer female
    • Breast cancer stage II
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Pembrolizumab
    Germany

  • Study of Pembrolizumab and Olaparib for Patients with Advanced HER2 Negative Breast Cancer and Specific Genetic Mutations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 negative breast cancer
    • Breast cancer male
    • Breast cancer metastatic
    Investigated Drugs:
    • Olaparib
    • Pembrolizumab
    Germany

  • Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Breast cancer male
    • Breast cancer stage I
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Capecitabine
    • Carboplatin
    Austria Belgium France Germany Ireland Spain
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!